Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Oct 2011
Randomized Controlled Trial Comparative StudyProof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. ⋯ Four years after vaccination of women who appeared to be uninfected, this nonrandomized analysis suggests that two doses of the HPV16/18 vaccine, and maybe even one dose, are as protective as three doses.
-
J. Natl. Cancer Inst. · Oct 2011
Randomized Controlled Trial Multicenter StudySequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
The combination of chemotherapy with thoracic radiotherapy (TRT) compared with TRT alone has been shown to confer a survival advantage for good performance status patients with stage III non-small cell lung cancer. However, it is not known whether sequential or concurrent delivery of these therapies is the optimal combination strategy. ⋯ Concurrent delivery of cisplatin-based chemotherapy with TRT confers a long-term survival benefit compared with the sequential delivery of these therapies.
-
J. Natl. Cancer Inst. · Sep 2011
Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Indications for adjuvant endocrine treatment of breast cancer have gradually increased over the past several years. We aimed to define subgroups of patients who may or may not benefit from adjuvant endocrine therapy. ⋯ A small subgroup of breast cancer patients who were 60 years or older and had hormone-responsive early-stage tumors up to 10 mm, and received no systemic adjuvant therapy, were not at increased risk of mortality compared with women in this age-group in the general population.